Supernus Pharmaceuticals Inc (SUPN)
30.24
+0.18
(+0.60%)
USD |
NASDAQ |
May 02, 16:00
30.24
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Gross Profit (Quarterly): 144.69M for Dec. 31, 2023
Gross Profit (Quarterly) Chart
Historical Gross Profit (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 144.69M |
September 30, 2023 | 134.28M |
June 30, 2023 | 114.47M |
March 31, 2023 | 130.30M |
December 31, 2022 | 144.37M |
September 30, 2022 | 151.48M |
June 30, 2022 | 149.59M |
March 31, 2022 | 134.57M |
December 31, 2021 | 142.06M |
September 30, 2021 | 130.38M |
June 30, 2021 | 116.30M |
March 31, 2021 | 115.98M |
December 31, 2020 | 125.02M |
September 30, 2020 | 133.75M |
June 30, 2020 | 118.34M |
March 31, 2020 | 90.82M |
December 31, 2019 | 96.33M |
September 30, 2019 | 97.32M |
June 30, 2019 | 100.65M |
March 31, 2019 | 81.79M |
December 31, 2018 | 111.75M |
September 30, 2018 | 98.79M |
June 30, 2018 | 95.86M |
March 31, 2018 | 87.15M |
December 31, 2017 | 84.28M |
Date | Value |
---|---|
September 30, 2017 | 76.15M |
June 30, 2017 | 71.97M |
March 31, 2017 | 54.63M |
December 31, 2016 | 58.60M |
September 30, 2016 | 53.38M |
June 30, 2016 | 48.88M |
March 31, 2016 | 42.16M |
December 31, 2015 | 40.89M |
September 30, 2015 | 37.11M |
June 30, 2015 | 33.92M |
March 31, 2015 | 27.12M |
December 31, 2014 | 28.95M |
September 30, 2014 | 21.37M |
June 30, 2014 | 28.01M |
March 31, 2014 | 8.587M |
December 31, 2013 | 9.268M |
September 30, 2013 | 1.224M |
June 30, 2013 | 0.277M |
March 31, 2013 | 0.147M |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 0.042M |
September 30, 2011 | 0.011M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (Quarterly) Range, Past 5 Years
90.82M
Minimum
Mar 2020
151.48M
Maximum
Sep 2022
124.77M
Average
130.30M
Median
Mar 2023
Gross Profit (Quarterly) Benchmarks
Dynavax Technologies Corp | 46.91M |
Ligand Pharmaceuticals Inc | 26.46M |
Pacira BioSciences Inc | 133.55M |
Esperion Therapeutics Inc | 20.80M |
Collegium Pharmaceutical Inc | 94.63M |